αVβ3 integrin
Anti-αVβ3 integrin Recombinant Antibody Products
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: IgG2 - kappa
- Application: FC, IP, ELISA, Neut, FuncS, IF, IHC
Compare
-
- Derivation: Humanized (from mouse)
- Species Reactivity: Human
- Type: ADCC enhanced antibody
- Application: FC, IP, ELISA, Neut, FuncS, IF
Compare
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Humanized IgG
- Application: ELISA
Compare
-
- Species Reactivity: Human
- Type: Mouse IgG1
- Application: ELISA, Inhib, FC
Compare
-
- Derivation: Chimeric (mouse/human)
- Species Reactivity: Human
- Type: Chimeric (mouse/human) IgG1
- Application: ELISA, Inhib, FC
Compare
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Humanized IgG1
- Application: ELISA, Inhib, FC
Compare
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Humanized scFv
- Application: ELISA
Compare
-
- Derivation: Humanized
- Species Reactivity: Human
- Type: Humanized Fab
- Application: ELISA
Compare
-
- Scaffold Name: 10-FnIII
- Target: αvβ3 Integrin
- Species Reactivity: Human
- Derivation: Phage display
Compare
-
- Scaffold Name: CTLA-4
- Target: αvβ3 integrin
- Species Reactivity: Human
- Derivation: Phage display
Compare
-
- Scaffold Name: Kunitz domains
- Target: αvβ3 integrin
- Species Reactivity: Human
- Derivation: Phage display
Compare
-
- Scaffold Name: RGD-containing proteins
- Target: αvβ3 Integrin
- Species Reactivity: Human
- Derivation: Phage display
Compare
More Infomation
Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
More Infomation
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
αVβ3 is a type of integrin that is a receptor for vitronectin. It consists of two components, integrin alpha V and integrin beta 3 (CD61), and is expressed by platelets. Furthermore, it is a receptor for phagocytosis on macrophages or dendritic cells. Integrin αVβ3 is potential drug target because abnormal expression of v3 is linked to the development and progression of various diseases. Inhibitors like etaracizumab may be used as antiangiogenics.